New drug combination for untreated peripheral T-cell lymphoma
Part of Cancer clinical trials.
This trial tests a new combination of two drugs, SHR2554 and liposomal mitoxantrone, as the first treatment for peripheral T-cell lymphoma (PTCL), a rare type of blood cancer. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a specific type of peripheral T-cell lymphoma (PTCL).
- You must not have received any previous cancer treatment for this condition.
- You must have at least one tumor that can be measured or seen on imaging scans.
- You must be in generally good health, with a performance status of 0 to 2, meaning you can care for yourself and are not bedridden.
- You must have adequate organ and bone marrow function, and no severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill (SHR2554) as maintenance therapy after your first treatment for peripheral T-cell lymphoma has worked. The goal is to see if it helps keep the cancer from coming back.
This trial tests a new drug called TR115 against the standard treatment options for people with peripheral T-cell lymphoma that has come back or hasn't responded to previous treatments. The goal is to see if TR115 can help shrink tumors and improve outcomes.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
This trial tests a new combination of two drugs—a chemotherapy called mitoxantrone hydrochloride liposome and an immunotherapy called enlonstobart—for people with peripheral T cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for people with a type of lymphoma called T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this combination can help shrink tumors or stop the cancer from growing.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.